CYSLTR1 binds CYSLTR1 antagonists

Stable Identifier
R-HSA-9684627
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Cysteinyl leukotriene receptor 1 (CYSLTR1) is a GPCR through which leukotriene D4 mediates bronchoconstriction. CYSLTR1 antagonists work by antagonising the effects of proinflammatory leukotrienes (such as LTC4, LTD4 and LTE4), resulting in decreased inflammation and decreased hyperresponsiveness of airways to immune challenges (Capra et al. 1998, Snyder & Fleisch 1989, Wendell et al. 2020). The CYSLTR1 antagonists listed here comprise approved (montelukast, pranlukast and zafirlukast) and investigational drugs used in asthma therapy.

Literature References
PubMed ID Title Journal Year
9504401 Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro

Capra, V, Bolla, M, Belloni, PA, Mezzetti, M, Folco, GC, Nicosia, S, Rovati, GE

Br. J. Pharmacol. 1998
2543269 Leukotriene receptor antagonists as potential therapeutic agents

Snyder, DW, Fleisch, JH

Annu. Rev. Pharmacol. Toxicol. 1989
Participants
Participates
Orthologous Events
Authored
Reviewed
Created
Cite Us!